BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...
news.stocktradersdaily6h
Trading (BCRX) With Integrated Risk Controls
Check the time stamp on this data. Updated AI-Generated Signals for Biocryst Pharmaceuticals Inc. (BCRX) available here: BCRX. Type a few symbols and Take a Trial. The signals for these will appear ...
BioCryst (BCRX) Gets a Buy from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 21 and set a price target of $10.00.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.
stocknews8d
3 Under-the-Radar Biotech Stocks Revolutionizing Healthcare
Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...
KeyCorp (NYSE:KEY) Receives $19.44 Consensus PT from Analysts
KeyCorp (NYSE:KEY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nineteen ratings firms ...